Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.

Lerchen HG, Stelte-Ludwig B, Berndt S, Sommer A, Dietz L, Rebstock AS, Johannes S, Marx L, Jörißen H, Mahlert C, Greven S.

Chemistry. 2019 Jun 21;25(35):8208-8213. doi: 10.1002/chem.201900441. Epub 2019 Apr 15.

PMID:
30869180
2.

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA.

Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135. eCollection 2018 Sep 25.

3.

Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.

Lerchen HG, Wittrock S, Stelte-Ludwig B, Sommer A, Berndt S, Griebenow N, Rebstock AS, Johannes S, Cancho-Grande Y, Mahlert C, Greven S, Terjung C.

Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15.

PMID:
30180286
4.

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.

Willuda J, Linden L, Lerchen HG, Kopitz C, Stelte-Ludwig B, Pena C, Lange C, Golfier S, Kneip C, Carrigan PE, Mclean K, Schuhmacher J, von Ahsen O, Müller J, Dittmer F, Beier R, El Sheikh S, Tebbe J, Leder G, Apeler H, Jautelat R, Ziegelbauer K, Kreft B.

Mol Cancer Ther. 2017 May;16(5):893-904. doi: 10.1158/1535-7163.MCT-16-0474. Epub 2017 Mar 14.

5.

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B.

Cancer Res. 2016 Nov 1;76(21):6331-6339. Epub 2016 Aug 19.

6.

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Müller-Tiemann B, Kreft B, Ziegelbauer K.

Mol Cancer Ther. 2014 Jun;13(6):1537-48. doi: 10.1158/1535-7163.MCT-13-0926. Epub 2014 Apr 8.

7.

Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.

Schirrmann T, Frenzel A, Linden L, Stelte-Ludwig B, Willuda J, Harrenga A, Dübel S, Müller-Tiemann B, Trautwein M.

MAbs. 2014 Mar-Apr;6(2):367-80. doi: 10.4161/mabs.27830. Epub 2014 Jan 15.

8.

Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.

Urbahns K, Härter M, Albers M, Schmidt D, Stelte-Ludwig B, Brüggemeier U, Vaupel A, Keldenich J, Lustig K, Tsujishita H, Gerdes C.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6151-4. Epub 2007 Sep 14.

PMID:
17910915
9.

[PDE5 inhibitors in treatment of benign prostatic syndrome].

Sandner P, Tinel H, Stelte-Ludwig B, Huetter J, Neuser D, Bischoff E, Ulbrich E.

Urologe A. 2007 Sep;46(9):1189-92. German. No abstract available.

PMID:
17609921
10.
11.

Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.

Urbahns K, Härter M, Vaupel A, Albers M, Schmidt D, Brüggemeier U, Stelte-Ludwig B, Gerdes C, Tsujishita H.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1071-4.

PMID:
12643914
12.

Biphenyls as potent vitronectin receptor antagonists.

Urbahns K, Härter M, Albers M, Schmidt D, Stelte-Ludwig B, Brüggemeier U, Vaupel A, Gerdes C.

Bioorg Med Chem Lett. 2002 Jan 21;12(2):205-8.

PMID:
11755355

Supplemental Content

Loading ...
Support Center